Recombinant anti-PD-…Biopharma) Drug Due Diligence 2026

This Recombinant anti-PD-L1/TGF-β bispecific antibody (Wuhan YZY Biopharma) Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 1/2

Highest phase

Registered trials

Result records

149

Matched deals

Executive recommendation: HOLD / OPTION

Decision memo

Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.

The central underwriting question is whether Recombinant anti-PD-L1/TGF-β bispecific antibody (Wuhan YZY Biopharma) can convert its Bispecific antibody profile and PDL1 x TGF-β biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Recombinant anti-PD-L1/TGF-β bispecific antibody (Wuhan YZY Biopharma) (query alias: Recombinant anti-PD-L1/TGF-β bispecific antibody (Wuhan YZY Biopharma))
Modality / target	Bispecific antibody; PDL1 x TGF-β; PDL1 inhibitors, TGF-β inhibitors
Highest global status	Phase 1/2
Originator	Wuhan YZY Biopharma Co., Ltd.
Active developers	Huazhong University of Science & Technology, Wuhan YZY Biopharma Co., Ltd.

The MCP disease footprint includes Advanced Pancreatic Adenocarcinoma, Neoplasms. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06266143	Phase 1/2	Completed	71	Primary endpoint not disclosed in English source
CTR20230372	Phase 1/2	Terminated	105	Primary endpoint not disclosed in English source
NCT05028556	Phase 1	Completed	50	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Evidence gap

The Clinical Trials MCP returned no matched public result record. This is a gating diligence gap, not evidence of failure.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Recombinant anti-PD-L1/TGF-β bispecific antibody (Wuhan YZY Biopharma) addresses Advanced Pancreatic Adenocarcinoma, Neoplasms. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Bispecific antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 149 matched transaction record(s) under the scope “target-level comparable: PDL1 x TGF-β.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: PDL1 x TGF-β records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-08-21	Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets	Discovery	US$150.0M stated total
2026-06-26	CStone Pharma joins hands with Arrotex to commercialise Sugemalimab across Australia and New Zealand	Approved	Financial terms not disclosed
2026-02-18	BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License	Not disclosed	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “TGF-beta inhibitors for use for treating resistant or unresponsive cancer in patients”. The milestone feed surfaced a patent-application signal described as “Pharmaceutical combination of antiviral agents targeting HBV and/or an immune modulator for treatment of hbv”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

HOLD / OPTION